Login

Andrew Dorman

ORCID: 0000-0002-5412-977X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5086751067
Research Areas
  • Glioma Diagnosis and Treatment
  • Neuroblastoma Research and Treatments
  • Cancer therapeutics and mechanisms
  • Boron Compounds in Chemistry
  • Brain Metastases and Treatment

Pfizer (United States)
 2013

 Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study
OPENALEX - Publications 
Jacques Grill Birgit Geoerger Lyle Gesner Danuta Perek Pierre Leblond and 13 more Adela Cañete Isabelle Aerts Luís Madero Josep Sanchez de Toledo Codina Joris Verlooy Edward J. Estlin Laura A. Cisar Aurora Breazna Andrew Dorman Simon Bailey Gary Nicolin Richard G. Grundy Darren Hargrave

This multicenter phase II study investigated temozolomide + irinotecan (TEMIRI) treatment in children with relapsed or refractory medulloblastoma.Patients received 100-125 mg/m(2)/day (days 1-5) and 10 1-5 8-12) every 3 weeks. The primary endpoint was tumor response within the first 4 cycles confirmed ≥4 weeks assessed by an external review committee (ERRC). In a 2-stage Optimum Simon design, ≥6 responses 15 evaluable patients were required for continued enrollment; total of 19 from 46...

10.1093/neuonc/not097 article EN Neuro-Oncology 2013-07-14
 A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study
OPENALEX - Publications 
Darren Hargrave Birgit Geoerger Didier Frappaz Torsten Pietsch Lyle Gesner and 14 more Laura A. Cisar Aurora Breazna Andrew Dorman Ofelia Cruz José Luís Fuster Xavier Rialland Céline Icher Pierre Leblond David M. Ashley Giorgio Perilongo Martin Elliott Martin English Niels Clausen Jacques Grill

10.1007/s11060-013-1098-2 article EN Journal of Neuro-Oncology 2013-03-03
Coming Soon ...